

Ted A Skolarus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5200526/publications.pdf>

Version: 2024-02-01

131
papers

2,646
citations

236612

25
h-index

233125

45
g-index

131
all docs

131
docs citations

131
times ranked

3834
citing authors

#	ARTICLE	IF	CITATIONS
1	American Cancer Society prostate cancer survivorship care guidelines. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 225-249.	157.7	324
2	Minimally Important Difference for the Expanded Prostate Cancer Index Composite Short Form. <i>Urology</i> , 2015, 85, 101-106.	0.5	241
3	Veterans Affairs Telemedicine: Bringing Urologic Care to Remote Clinics. <i>Urology</i> , 2015, 86, 255-261.	0.5	96
4	Survivorship and Improving Quality of Life in Men with Prostate Cancer. <i>European Urology</i> , 2015, 68, 374-383.	0.9	91
5	Exploring the role of the partner in couples'™ sexual recovery after surgery for prostate cancer. <i>Supportive Care in Cancer</i> , 2014, 22, 2509-2515.	1.0	75
6	Telemedicine in Urology: State of the Art. <i>Urology</i> , 2016, 94, 10-16.	0.5	74
7	Assessing citation networks for dissemination and implementation research frameworks. <i>Implementation Science</i> , 2017, 12, 97.	2.5	73
8	Sharpening the focus on causes and timing of readmission after radical cystectomy for bladder cancer. <i>Cancer</i> , 2014, 120, 1409-1416.	2.0	65
9	Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. <i>Radiotherapy and Oncology</i> , 2015, 116, 179-184.	0.3	61
10	What Couples Say about Their Recovery of Sexual Intimacy after Prostatectomy: Toward the Development of a Conceptual Model of Couples' Sexual Recovery after Surgery for Prostate Cancer. <i>Journal of Sexual Medicine</i> , 2015, 12, 494-504.	0.3	59
11	Symptom burden and information needs in prostate cancer survivors: a case for tailored long-term survivorship care. <i>BJU International</i> , 2016, 118, 372-378.	1.3	56
12	Reducing Hospital Readmissions by Integrating Empirical Prediction with Resource Optimization. <i>Production and Operations Management</i> , 2016, 25, 233-257.	2.1	55
13	Understanding fragmentation of prostate cancer survivorship care. <i>Cancer</i> , 2012, 118, 2837-2845.	2.0	49
14	Association of the Hospital Readmissions Reduction Program With Surgical Readmissions. <i>JAMA Surgery</i> , 2018, 153, 243.	2.2	45
15	Understanding Hospital Readmission Intensity after Radical Cystectomy. <i>Journal of Urology</i> , 2015, 193, 1500-1506.	0.2	43
16	Predictors and Cost of Readmission in Total Knee Arthroplasty. <i>Journal of Arthroplasty</i> , 2018, 33, 2759-2763.	1.5	42
17	Regional Variation in Quality of Prostate Cancer Care. <i>Journal of Urology</i> , 2014, 191, 957-963.	0.2	41
18	Does Robotic Technology Mitigate the Challenges of Large Prostate Size?. <i>Urology</i> , 2010, 76, 1117-1121.	0.5	40

#	ARTICLE	IF	CITATIONS
19	The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future. <i>European Urology</i> , 2020, 78, 731-742.	0.9	39
20	The Economic Burden of Prostate Cancer Survivorship Care. <i>Journal of Urology</i> , 2010, 184, 532-538.	0.2	34
21	Quality of prostate cancer care among rural men in the Veterans Health Administration. <i>Cancer</i> , 2013, 119, 3629-3635.	2.0	31
22	Primary care perspectives on prostate cancer survivorship: Implications for improving quality of care. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 727-732.	0.8	30
23	Missed Opportunities in Preventing Hospital Readmissions: Redesigning Post-Discharge Checkup Policies. <i>Production and Operations Management</i> , 2018, 27, 2226-2250.	2.1	30
24	Regional Differences in Early Stage Bladder Cancer Care and Outcomes. <i>Urology</i> , 2010, 76, 391-396.	0.5	27
25	No Differences in Population-based Readmissions After Open and Robotic-assisted Radical Cystectomy: Implications for Post-discharge Care. <i>Urology</i> , 2017, 104, 77-83.	0.5	27
26	Preparing Patients and Partners for Recovery From the Side Effects of Prostate Cancer Surgery: A Group Approach. <i>Urology</i> , 2016, 88, 36-42.	0.5	26
27	A Model to Optimize Followup Care and Reduce Hospital Readmissions after Radical Cystectomy. <i>Journal of Urology</i> , 2016, 195, 1362-1367.	0.2	26
28	Sharp Decline In Prostate Cancer Treatment Among Men In The General Population, But Not Among Diagnosed Men. <i>Health Affairs</i> , 2017, 36, 108-115.	2.5	25
29	Self-Management in Long-Term Prostate Cancer Survivors: A Randomized, Controlled Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 1326-1335.	0.8	23
30	Association Between Hospital Participation in Medicare Shared Savings Program Accountable Care Organizations and Readmission Following Major Surgery. <i>Annals of Surgery</i> , 2019, 269, 873-878.	2.1	23
31	A measure of case complexity for streamlining workflow in multidisciplinary tumor boards: Mixed methods development and early validation of the MeDiC tool. <i>Cancer Medicine</i> , 2020, 9, 5143-5154.	1.3	23
32	Monitoring Quality of Life Among Prostate Cancer Survivors: The Feasibility of Automated Telephone Assessment. <i>Urology</i> , 2012, 80, 1021-1026.	0.5	22
33	Androgen-deprivation-associated bone disease. <i>Current Opinion in Urology</i> , 2014, 24, 601-607.	0.9	21
34	Early effect of Medicare Shared Savings Program accountable care organization participation on prostate cancer care. <i>Cancer</i> , 2018, 124, 563-570.	2.0	20
35	External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer. <i>Journal of Urology</i> , 2019, 202, 518-524.	0.2	20
36	Use of Restaging Bladder Tumor Resection for Bladder Cancer Among Medicare Beneficiaries. <i>Urology</i> , 2011, 78, 1345-1349.	0.5	19

#	ARTICLE	IF	CITATIONS
37	Negative information-seeking experiences of long-term prostate cancer survivors. <i>Journal of Cancer Survivorship</i> , 2016, 10, 1089-1095.	1.5	19
38	Too Much Surgery. <i>Annals of Surgery</i> , 2020, 271, 1020-1022.	2.1	19
39	Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 415.e1-415.e6.	0.8	18
40	Adoption of Abiraterone and Enzalutamide by Urologists. <i>Urology</i> , 2019, 131, 176-183.	0.5	18
41	Implications of Prostate Cancer Treatment in Men With Inflammatory Bowel Disease. <i>Urology</i> , 2017, 104, 131-136.	0.5	17
42	Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 462-469.	0.8	17
43	Functional Outcomes Following Nerve Sparing Prostatectomy Augmented with Seminal Vesicle Sparing Compared to Standard Nerve Sparing Prostatectomy: Results from a Randomized Controlled Trial. <i>Journal of Urology</i> , 2017, 198, 600-607.	0.2	16
44	The implications of baseline bone health assessment at initiation of androgen deprivation therapy for prostate cancer. <i>BJU International</i> , 2018, 121, 558-564.	1.3	16
45	Characterizing the Benign Prostatic Hyperplasia Literature: A Bibliometric Analysis. <i>Urology</i> , 2020, 136, 202-211.	0.5	15
46	The Delivery of Prostate Cancer Care in the United States: Implications for Delivery System Reform. <i>Journal of Urology</i> , 2010, 184, 2279-2284.	0.2	14
47	Understanding the Relationship Between Tumor Size, Gland Size, and Disease Aggressiveness in Men With Prostate Cancer. <i>Urology</i> , 2014, 84, 373-379.	0.5	14
48	Variation in readmission expenditures after high-risk surgery. <i>Journal of Surgical Research</i> , 2017, 213, 60-68.	0.8	14
49	Potential Implications of Shortening Length of Stay Following Radical Cystectomy in a Pre-ERAS Population. <i>Urology</i> , 2017, 102, 92-99.	0.5	14
50	Health Care Integration and Quality among Men with Prostate Cancer. <i>Journal of Urology</i> , 2017, 197, 55-60.	0.2	14
51	Adherence to Performance Measures and Outcomes among Men Treated for Prostate Cancer. <i>Journal of Urology</i> , 2014, 192, 743-748.	0.2	13
52	A Multi-Center International Study Assessing the Impact of Differences in Baseline Characteristics and Perioperative Care Following Radical Cystectomy. <i>Bladder Cancer</i> , 2016, 2, 251-261.	0.2	13
53	The Fate of Radical Cystectomy Patients after Hospital Discharge: Understanding the Black Box of the Pre-readmission Interval. <i>European Urology Focus</i> , 2018, 4, 711-717.	1.6	13
54	Comparison of Neoadjuvant and Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 201-209.e2.	0.9	13

#	ARTICLE	IF	CITATIONS
55	Are We Targeting the Right Outcome for Sexual Health After Prostate Cancer Treatment?. <i>European Urology</i> , 2015, 68, 550-551.	0.9	12
56	TrueNTH Sexual Recovery Intervention for couples coping with prostate cancer: Randomized controlled trial results. <i>Cancer</i> , 2022, 128, 1513-1522.	2.0	12
57	Rethinking Patient-Physician Communication of Biopsy Resultsâ€”The Waiting Game. <i>JAMA Oncology</i> , 2015, 1, 1025.	3.4	11
58	Limitations of Prostate-specific Antigen Testing After a Prostate Cancer Diagnosis. <i>European Urology</i> , 2016, 70, 209-210.	0.9	11
59	The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration. <i>Journal of Urology</i> , 2018, 200, 541-548.	0.2	11
60	Telemedicine and prostate cancer survivorship: a narrative review. <i>MHealth</i> , 2018, 4, 45-45.	0.9	11
61	Role of Postâ€”Acute Care on Hospital Readmission After High-Risk Surgery. <i>Journal of Surgical Research</i> , 2019, 234, 116-122.	0.8	11
62	Urinary incontinence and use of incontinence surgery after radical prostatectomy: a national study using patientâ€”reported outcomes. <i>BJU International</i> , 2022, 130, 84-91.	1.3	11
63	Dissecting Surgeon Behavior. <i>Annals of Surgery</i> , 2018, 267, 432-434.	2.1	10
64	Adherence and outâ€”ofâ€”pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer. <i>Cancer</i> , 2020, 126, 5050-5059.	2.0	10
65	Estimating the rate and reasons of clinical trial failure in urologic oncology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 154-160.	0.8	10
66	Using implementation science to improve urologic oncology care. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 384-387.	0.8	9
67	Using Implementation Science to Examine the Impact of Cancer Survivorship Care Plans. <i>Journal of Clinical Oncology</i> , 2016, 34, 3834-3837.	0.8	9
68	Accountable Care Organizations and Prostate Cancer Care. <i>Urology Practice</i> , 2017, 4, 454-461.	0.2	9
69	De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT). <i>Implementation Science</i> , 2018, 13, 144.	2.5	9
70	Inaugural Readmission Penalties for Total Hip and Total Knee Arthroplasty Procedures Under the Hospital Readmissions Reduction Program. <i>JAMA Network Open</i> , 2019, 2, e1916008.	2.8	9
71	Population Analysis of Male Urethral Stricture Management and Urethroplasty Success in the United States. <i>Urology</i> , 2019, 123, 258-264.	0.5	9
72	Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 734.e1-734.e10.	0.8	9

#	ARTICLE	IF	CITATIONS
73	Aligning Urology Residency Training With Real-World Workforce Needs. <i>Journal of Surgical Education</i> , 2021, 78, 820-827.	1.2	9
74	Recurrence, metastasis, and survival after radical prostatectomy in the era of advanced treatments. <i>Journal of Clinical Oncology</i> , 2022, 40, 5090-5090.	0.8	9
75	Accuracy of Prostate-Specific Antigen Values in Prostate Cancer Registries. <i>Journal of Clinical Oncology</i> , 2016, 34, 3586-3587.	0.8	8
76	Multilingual Self-Management Resources for Prostate Cancer Survivors and Their Partners: Results of a Long-Term Academic-State Health Department Partnership to Promote Survivorship Care. <i>Urology</i> , 2017, 110, 92-97.	0.5	8
77	Enhancing prostate cancer survivorship care through self-management. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 564-568.	0.8	8
78	Treatment of ureteral anastomotic strictures with reimplantation and survival after cystectomy and urinary diversion. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 33.e1-33.e9.	0.8	8
79	Variation in prostate cancer treatment and spending among Medicare shared savings program accountable care organizations. <i>Cancer</i> , 2018, 124, 3364-3371.	2.0	8
80	Technology Diffusion and Prostate Cancer Quality of Care. <i>Urology</i> , 2014, 84, 1066-1072.	0.5	7
81	Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 376-386.	0.4	7
82	Urologist Practice Structure and Spending for Prostate Cancer Care. <i>Urology</i> , 2019, 130, 65-71.	0.5	7
83	Prostate cancer survivorship care in the Veterans Health Administration. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2014, 31, 10-17.	0.6	7
84	Determinants of quality prostate cancer survivorship care across the primary and specialty care interface: Lessons from the Veterans Health Administration. <i>Cancer Medicine</i> , 2019, 8, 2686-2702.	1.3	6
85	Factors influencing treatment of veterans with advanced prostate cancer. <i>Cancer</i> , 2021, 127, 2311-2318.	2.0	6
86	Using an Automated Electronic Health Record Score To Estimate Life Expectancy In Men Diagnosed With Prostate Cancer In The Veterans Health Administration. <i>Urology</i> , 2021, 155, 70-76.	0.5	6
87	Understanding Early Functional Recovery After Robotic Prostatectomy. <i>Surgical Innovation</i> , 2012, 19, 5-10.	0.4	5
88	Impact of Accountable Care Organizations on Diagnostic Testing for Prostate Cancer. <i>Urology</i> , 2018, 116, 68-75.	0.5	5
89	Implications of Cystectomy Travel Distance for Hospital Readmission and Survival. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1171-e1180.	0.9	5
90	Comparison of readmission and early revision rates as a quality metric in total knee arthroplasty using the Nationwide Readmission Database. <i>Annals of Translational Medicine</i> , 2020, 8, 687-687.	0.7	5

#	ARTICLE	IF	CITATIONS
91	Improving Guideline Adherence in Urology. <i>European Urology Focus</i> , 2022, 8, 1545-1552.	1.6	5
92	Implementation of patient-reported outcome measures into health care for men with localized prostate cancer. <i>Nature Reviews Urology</i> , 2022, 19, 263-279.	1.9	5
93	Envisioning clinical trials as complex interventions. <i>Cancer</i> , 2022, 128, 3145-3151.	2.0	5
94	Characterising "bounce-back"™ readmissions after radical cystectomy. <i>BJU International</i> , 2019, 124, 955-961.	1.3	4
95	Urology Workforce Changes and Implications for Prostate Cancer Care Among Medicare Enrollees. <i>Urology</i> , 2021, 155, 77-82.	0.5	4
96	Learning from the "etail end" of de-implementation: the case of chemical castration for localized prostate cancer. <i>Implementation Science Communications</i> , 2021, 2, 124.	0.8	4
97	Characterising potential bone scan overuse amongst men treated with radical prostatectomy. <i>BJU International</i> , 2019, 124, 55-61.	1.3	3
98	Urologist Practice Structure and Quality of Prostate Cancer Care. <i>Urology Practice</i> , 2020, 7, 419-424.	0.2	3
99	Prostate cancer clinical trial completion: The role of geography. <i>Contemporary Clinical Trials</i> , 2021, 111, 106600.	0.8	3
100	Early national dissemination of abiraterone and enzalutamide for advanced prostate cancer in Medicare Part D.. <i>Journal of Clinical Oncology</i> , 2017, 35, 35-35.	0.8	3
101	Comparison of the treatment of men with prostate cancer between the US and England: an international population-based study. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 287-292.	2.0	3
102	Re: Neil E. Martin, Laura Massey, Caleb Stowell, et al. Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. <i>Eur Urol</i> 2015;67:460-7. <i>European Urology</i> , 2016, 69, e125-e126.	0.9	2
103	Providing prostate cancer survivorship care in Japan: Implications from the USA care model. <i>International Journal of Urology</i> , 2016, 23, 906-915.	0.5	2
104	Castration remains despite decreasing definitive treatment of localized prostate cancer in the elderly: A case for de-implementation. <i>Cancer</i> , 2018, 124, 3971-3974.	2.0	2
105	Association between PSA values and surveillance quality after prostate cancer surgery. <i>Cancer Medicine</i> , 2019, 8, 7903-7912.	1.3	2
106	Spillover Effects of the Hospital Readmissions Reduction Program on Radical Cystectomy Readmissions. <i>Urology Practice</i> , 2019, 6, 350-356.	0.2	2
107	Resurrecting immortal-time bias in the study of readmissions. <i>Health Services Research</i> , 2020, 55, 273-276.	1.0	2
108	Dynamic readmission prediction using routine postoperative laboratory results after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 255-261.	0.8	2

#	ARTICLE	IF	CITATIONS
109	Primary Care Providers'™ Perceptions About Participating in Low-Risk Prostate Cancer Treatment Decisions. <i>Journal of General Internal Medicine</i> , 2021, 36, 447-454.	1.3	2
110	The State of Men's™ Health Services in the Veterans Health Administration. <i>Current Urology Reports</i> , 2017, 18, 88.	1.0	2
111	Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide. <i>Urology</i> , 2022, 161, 50-58.	0.5	2
112	Primary care perspectives on Prostate cancer screening. <i>Nurse Practitioner</i> , 2011, 36, 39-44.	0.2	1
113	Reframing Financial Incentives Around Reducing Readmission After Radical Cystectomy. <i>Urology</i> , 2020, 142, 99-105.	0.5	1
114	Designing lean, efficient clinical trials is an ethical imperative: the fragility index should not be used in the design of randomized clinical trials. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 738-739.	0.8	1
115	Exploring Variation in the Receipt of Recommended Active Surveillance for Men with Favorable-Risk Prostate Cancer. <i>Journal of Urology</i> , 2022, 208, 600-608.	0.2	1
116	Editorial Comment. <i>Urology</i> , 2015, 85, 627-628.	0.5	0
117	Reply. <i>Urology</i> , 2015, 86, 260-261.	0.5	0
118	Author Reply. <i>Urology</i> , 2017, 102, 99.	0.5	0
119	Introduction to a Seminar on implementation and de-implementation to improve urologic cancer care. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 244-245.	0.8	0
120	Editorial Comment. <i>Journal of Urology</i> , 2018, 199, 1172-1173.	0.2	0
121	3104 Characterizing the top 100 articles in benign prostatic hyperplasia literature using bibliometric analysis. <i>Journal of Clinical and Translational Science</i> , 2019, 3, 27-27.	0.3	0
122	Understanding Active Surveillance for Prostate Cancer. <i>JCO Oncology Practice</i> , 2021, 17, OP.20.00929.	1.4	0
123	EDITORIAL COMMENT. <i>Urology</i> , 2021, 153, 145-146.	0.5	0
124	Considerations in the Analysis of Clinical Trial Failure. <i>Journal of Urology</i> , 2022, 207, 9-11.	0.2	0
125	AUTHOR REPLY. <i>Urology</i> , 2021, 155, 76.	0.5	0
126	Prognostic significance of perineural invasion in localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 30-30.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Self-management in prostate cancer survivors: A randomized controlled trial.. Journal of Clinical Oncology, 2018, 36, 5011-5011.	0.8	0
128	Prostate Cancer Surveillance After Radiation Therapy in a National Delivery System. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2019, 36, S16-S21.	0.6	0
129	Catheter management after benign transurethral prostate surgery: RAND/UCLA Appropriateness Criteria. American Journal of Managed Care, 2019, 25, e366-e372.	0.8	0
130	Better Understanding the Timing of Androgen Deprivation (TOAD) Trial Outcomes: Impacts of Prior ADT. JNCI Cancer Spectrum, 0, , .	1.4	0
131	Unpacking low-value castration practices using behavior specification to guide de-implementation in prostate cancer care.. Journal of Clinical Oncology, 2022, 40, e17055-e17055.	0.8	0